Literature DB >> 11720746

Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer.

A Neuner1, M Schindel, U Wildenberg, T Muley, H Lahm, J R Fischer.   

Abstract

Increased production of immunosuppressive IL-10 by non-small cell lung cancer (NSCLC) and increased plasma IL-10 concentrations in NSCLC-patients have recently been correlated to reduced survival. We earlier demonstrated suppression of IL-2 secretion in NSCLC-patients. We now analyzed the influence of IL-2 suppression on survival in NSCLC-patients and influence of IL-10 on IL-2 secretion. The correlation of the IL-2-concentration in whole blood cell cultures from 90 NSCLC-patients at the time of diagnosis to survival was analyzed by using crit-level, the Kaplan-Meier method and the log-rank test. IL-2 secretion capacity at the time of diagnosis significantly influenced survival in NSCLC-patients. With a cut-off value for IL-2 of 1100 pg/ml, the difference in survival was significant with a P-value of 0.014 in the whole patient group. In the subgroup of surgically treated patients (n=33), survival was different with a P-value of 0.011. Moreover, secretion of IL-2 was inhibited in a dose-dependent manner upon addition of IL-10 in whole blood cell cultures from normal individuals. Thus, suppression of IL-2 secretion is predictive for survival of NSCLC-patients and may be mediated by tumor-derived IL-10.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720746     DOI: 10.1016/s0169-5002(01)00350-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Alveolar macrophage function is altered in patients with lung cancer.

Authors:  D S Pouniotis; M Plebanski; V Apostolopoulos; C F McDonald
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 2.  Lung cancer vaccines: current status and future prospects.

Authors:  Charmaine A Ramlogan-Steel; Jason C Steel; John C Morris
Journal:  Transl Lung Cancer Res       Date:  2014-02

3.  Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

Authors:  K V Woan; M Lienlaf; P Perez-Villaroel; C Lee; F Cheng; T Knox; D M Woods; K Barrios; J Powers; E Sahakian; H W Wang; J Canales; D Marante; K S M Smalley; J Bergman; E Seto; A Kozikowski; J Pinilla-Ibarz; A Sarnaik; E Celis; J Weber; E M Sotomayor; A Villagra
Journal:  Mol Oncol       Date:  2015-04-24       Impact factor: 6.603

4.  Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer.

Authors:  Rui Li; Dominik Rüttinger; Rong Li; Lü-Sheng Si; Yi-Li Wang
Journal:  Langenbecks Arch Surg       Date:  2003-09-19       Impact factor: 3.445

5.  The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice.

Authors:  Ji-Yan Liu; Xiao-Shi Zhang; Ya Ding; Rui-Qing Peng; Xia Cheng; Nian-Hua Zhang; Jian-Chuan Xia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2005-01-28       Impact factor: 5.531

6.  Anti-α-enolase is a prognostic marker in postoperative lung cancer patients.

Authors:  Kuan-Chung Hsiao; Neng-Yao Shih; Pei-Yi Chu; Yi-Mei Hung; Jia-Yi Liao; Shao-Wen Chou; Yi-Yuan Yang; Gee-Chen Chang; Ko-Jiunn Liu
Journal:  Oncotarget       Date:  2015-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.